ACTRN12616000203459
Completed
未知
Increasing the effectiveness of treatment with continuous positive airways pressure (CPAP) using a weight-management program in overweight adults with sleep apnoea : the Sleeping Well Trial
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Sleep Apnoea
- Sponsor
- Monash University
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adults aged 19\-68 years who have been newly diagnosed with moderate\-severe untreated OSA with AHI greater than 20 events/hr (AASM alternate criteria) (demonstrated by prior overnight polysomnography \[PSG]). Participants must be overweight with a body mass index (BMI) for Caucasians between 25 and 43 kg/m2 and for those of Asian and Indian descent 23 and 43 and self report a sedentary lifestyle ((self\-reported exercise less than 2 days/week and a duration of less than 45 minutes per session. Eligible participants are required to be eligible to use Fixed\-Pressure Continuous Positive Airway Pressure (CPAP).
Exclusion Criteria
- •1\. Pregnant women
- •2\. Diagnosed with concomitant obesity hypoventilation syndrome, Diabetes mellitus type 1, severe psychiatric disorder, and drowsiness
- •3\. Required to use VPAP or BPAP (variable/bilevel positive airway pressure)
- •4\. Unable to exercise (e.g. due to orthopedic or musculoskeletal problems)
- •5\. Previous surgical or current medical treatment for OSA
- •6\. Previous bariatric surgery
- •7\. Current use of weight loss programs and/or weight loss drugs
- •8\. Recent angina pectoris or atrial fibrillation
- •9\. Insufficient knowledge of English language to be able to consent
- •10\. Unable to provide informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Ayurvedic Rasayana treatment as an addon therapy to improve the results in management of coronavirus diseaseHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J101- Influenza due to other identifiedinfluenza virus with other respiratory manifestationsCTRI/2020/07/026343Ayurved Rasayani100
Completed
Not Applicable
Efficacy of new treatment (proactive treatment) for the maintenance of atopic dermatitisatopic dermatitisJPRN-UMIN000017935Department of Dermatology, Keio University School of Medicine40
Completed
Not Applicable
Vaginal progesterone plus cervical pessary for preventing preterm birthIRCT201603109568N15Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences144
Not yet recruiting
Not Applicable
Test of a strategy for childhood obesity based on the Food Guide for the Brazilian PopulatioRBR-3st5snHospital Universitário Pedro Ernesto
Active, not recruiting
Phase 1
The effectiveness of pharmacological treatment with the glucagon-like peptide-1 receptor agonist Liraglutide 3mg (Saxenda®) once-daily for weight management in forensic psychiatryEUCTR2020-003718-11-DKMental Health Center Copenhagen40